I kliniske undersøgelser med aripiprazol sås ingen signifikant forskel i forekomst af hyperglykæmirelaterede bivirkninger (herunder diabetes) eller i abnorme glykæmiske laboratorieværdier sammenlignet med placebo.
In clinical trials with aripiprazole, there were no significant differences in the incidence rates of hyperglycaemia-related adverse events (including diabetes) or in abnormal glycaemia laboratory values compared to placebo.